Category Competitive Intelligence

Rethinking Pharmaceutical Competitive Intelligence in 2016

Most of the pharmaceutical companies continues to face crescent competition in the operating markets from different sources. Some of the solutions to overcome the current difficulties and barriers, may be a constant search of new R&D methods and new operations mechanisms in order to obtain economic scale and gain new commercial capabilities that can drive or improve effectiveness from R&D investments.

Understanding Centricity Antonio Pesqueira

Making the Multichannel Marketing (MCM) Strategy Relevant in Life Sciences: 2016 perspectives (Part IV)

Online and digital are no longer meaningless concepts to most of the patients, where a large percentage of them across most of the EU countries are using already apps to compare drug prices, learn more about diseases, search for new physicians (2nd opinions) or treatments. In this growing environment are the current pharma companies being able and flexible to support the necessary knowledge development on their products and with that leverage not only the patient’s awareness around the product, but as well the doctor’s knowledge and engagement? How important is the word-of-mouth for Pharma in 2016?

Understanding Centricity Antonio Pesqueira

The rise of Multichannel Marketing and Digital in Pharma: A Business Necessity (Part II)

Although pharma continues to struggle in this new complex terms, the access to physicians, markets and information is getting harder and all the related barriers increased and more difficult to fight with.
Pharmaceutical companies operating in the global marketplace are realizing that in order to derive their revenues should be able to deliver in a more systematic way innovation and critical business value, being also able to find and search new innovative business models that allows the company to have a better perspective in a larger competitive canvas.

The hidden connections between Competitive Intelligence and Innovation in Pharma

Most of the pharmaceutical companies continues to face crescent competition in the operating markets from different sources. Some of the solutions to overcome the current difficulties and barriers, may be a constant search of new R&D methods and new operations mechanisms in order to obtain economic scale and gain new commercial capabilities that can drive or improve effectiveness from R&D investments.